Hoekman K - Search Results

Year	Number of Results
1982	1
1984	1
1985	2
1986	1
1987	1
1989	2
1990	1
1991	7
1992	3
1993	3
1994	4
1995	4
1996	7
1997	9
1998	1
1999	9
2000	8
2001	3
2002	7
2003	10
2004	8
2005	6
2006	4
2007	6
2008	3
2009	4
2010	3
2011	1
2012	1
2013	1
2014	1
2024	0

1

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Vergote I, et al. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806. N Engl J Med. 2010. PMID: 20818904 Free article. Clinical Trial.

2

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

van Cruijsen H, van der Veldt A, Hoekman K. van Cruijsen H, et al. Among authors: hoekman k. Front Biosci (Landmark Ed). 2009 Jan 1;14(6):2248-68. doi: 10.2741/3377. Front Biosci (Landmark Ed). 2009. PMID: 19273199 Free article. Review.

3

SU6668, a multitargeted angiogenesis inhibitor.

Hoekman K. Hoekman K. Cancer J. 2001 Nov-Dec;7 Suppl 3:S134-8. Cancer J. 2001. PMID: 11779084 Review.

4

Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Hoekman K, van der Vijgh WJ, Vermorken JB. Hoekman K, et al. Drugs. 1999 Feb;57(2):133-55. doi: 10.2165/00003495-199957020-00002. Drugs. 1999. PMID: 10188757 Review.

5

Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Verstappen CC, et al. Among authors: hoekman k. Drugs. 2003;63(15):1549-63. doi: 10.2165/00003495-200363150-00003. Drugs. 2003. PMID: 12887262 Review.

6

Proteomics of the TRAP-induced platelet releasate.

Piersma SR, Broxterman HJ, Kapci M, de Haas RR, Hoekman K, Verheul HM, Jiménez CR. Piersma SR, et al. Among authors: hoekman k. J Proteomics. 2009 Feb 15;72(1):91-109. doi: 10.1016/j.jprot.2008.10.009. Epub 2008 Nov 8. J Proteomics. 2009. PMID: 19049909

7

A doxorubicin-CNGRC-peptide conjugate with prodrug properties.

van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, Boven E, Hoekman K, Pinedo HM. van Hensbergen Y, et al. Among authors: hoekman k. Biochem Pharmacol. 2002 Mar 1;63(5):897-908. doi: 10.1016/s0006-2952(01)00928-5. Biochem Pharmacol. 2002. PMID: 11911842

8

DNA rearrangement as a marker of B and T cell malignancies.

Hoekman K, Brand A, Giphart MJ. Hoekman K, et al. Neth J Med. 1987 Dec;31(5-6):241-50. Neth J Med. 1987. PMID: 2893303 Review. No abstract available.

9

Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies.

van Cruijsen H, Giaccone G, Hoekman K. van Cruijsen H, et al. Among authors: hoekman k. Int J Cancer. 2005 Dec 20;117(6):883-8. doi: 10.1002/ijc.21479. Int J Cancer. 2005. PMID: 16152621 Review.

10

Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.

Broxterman HJ, Lankelma J, Hoekman K. Broxterman HJ, et al. Among authors: hoekman k. Drug Resist Updat. 2003 Jun;6(3):111-27. doi: 10.1016/s1368-7646(03)00026-8. Drug Resist Updat. 2003. PMID: 12860459 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Results by year